UTAH MEDICAL PRODUCTS INCUTMD
ASignal's systematic analysis rates UTMD as Neutral.
Reflects the latest available analysis · analyzed Oct 15, 2026
The case on UTMD
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health with debt-to-equity ratio of 0.00x
- High gross margin of 57.90% indicating pricing power
- Exceptional liquidity with current ratio of 48.62x
- Positive free cash flow of $8.84M
- Low beta of 0.39x indicating lower volatility
- Negative revenue growth of -14.30% year-over-year
- Declining earnings growth at -10.50% year-over-year
- High PEG ratio of 4.25x suggesting overvaluation relative to growth
- Only one news source (Yahoo) available, limited sentiment data
- No Reddit mentions, indicating low retail investor interest
See the full verdict on UTMD
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes UTMD
Most investors never get a second opinion, let alone several. ASignal runs UTMD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.